Reference Tool
Compare Compounds
Place up to three reference compounds side by side to compare their molecular profile, pharmacokinetics, and handling.
| Attribute | retatrutide | tirzepatide | retatrutide |
|---|---|---|---|
| Field of Medicine | Endocrinology · Metabolic Research | Endocrinology · Metabolic Research | Endocrinology · Metabolic Research |
| Category | incretin | incretin | incretin |
| Formula | — | C225H348N48O68 | — |
| Molecular Weight | ~4731 Da | 4813.5 Da | ~4731 Da |
| Sequence | 39-amino-acid triple agonist (GLP-1 / GIP / glucagon) | 39-amino-acid peptide with C20 fatty diacid moiety | 39-amino-acid triple agonist (GLP-1 / GIP / glucagon) |
| CAS Number | — | 2023788-19-2 | — |
| Half-Life | ~6 days | ~5 days (preclinical / published clinical literature) | ~6 days |
| Route (research) | Subcutaneous in research models | Subcutaneous in research models | Subcutaneous in research models |
| Onset / Steady-state | — | Steady-state typically reached after ~4 weeks of weekly dosing | — |
| Lyophilized Storage | −20°C long term; 2–8°C short term (weeks). Protect from light. | −20°C long term; 2–8°C short term (weeks). Protect from light. | −20°C long term; 2–8°C short term (weeks). Protect from light. |
| Reconstituted Storage | 2–8°C, generally up to 14–28 days depending on compound. | 2–8°C, generally up to 14–28 days depending on compound. | 2–8°C, generally up to 14–28 days depending on compound. |